US6653341B1
(en)
|
1998-06-17 |
2003-11-25 |
Eisai Co., Ltd. |
Methods and compositions for use in treating cancer
|
US8097648B2
(en)
*
|
1998-06-17 |
2012-01-17 |
Eisai R&D Management Co., Ltd. |
Methods and compositions for use in treating cancer
|
BRPI9911326B8
(pt)
|
1998-06-17 |
2021-05-25 |
Eisai Co Ltd |
análogos macrocíclicos e métodos para seu uso e preparação
|
DE10037310A1
(de)
|
2000-07-28 |
2002-02-07 |
Asta Medica Ag |
Neue Indolderivate und deren Verwendung als Arzneimittel
|
EP1531846A4
(en)
*
|
2002-02-27 |
2006-04-19 |
Us Gov Health & Human Serv |
CONJUGATES OF LIGAND, LINK AND CYTOTOXIC AGENS, AND RELATED COMPOSITIONS AND USE PROCESSES
|
AU2003228354B8
(en)
|
2002-03-22 |
2010-03-04 |
Eisai R&D Management Co., Ltd. |
Hemiasterlin derivatives and uses thereof in the treatment of cancer
|
US20050075395A1
(en)
*
|
2003-05-28 |
2005-04-07 |
Gary Gordon |
Continuous dosing regimen
|
JP2007500240A
(ja)
*
|
2003-05-29 |
2007-01-11 |
アボット・ラボラトリーズ |
Abt−751による持続投与レジメン
|
US20070196418A1
(en)
*
|
2003-07-29 |
2007-08-23 |
Michael Lewis |
Drug delivery methods and devices
|
CN1993342A
(zh)
*
|
2004-06-03 |
2007-07-04 |
卫材株式会社 |
用于制备软海绵素b的中间体
|
EP2522663B1
(en)
|
2004-06-03 |
2015-04-01 |
Eisai R&D Management Co., Ltd. |
Intermediates for the preparation of halichondrin B
|
US20060045846A1
(en)
*
|
2004-08-30 |
2006-03-02 |
Horstmann Thomas E |
Reagents and methods for labeling terminal olefins
|
WO2006076100A2
(en)
*
|
2004-12-09 |
2006-07-20 |
Eisai Co. Ltd. |
Tubulin isotype screening in cancer therapy using halichondrin b analogs
|
US8093410B2
(en)
|
2007-10-03 |
2012-01-10 |
Eisai R&D Management Co., Ltd. |
Intermediates and methods for the synthesis of halichondrin B analogs
|
JP6001857B2
(ja)
*
|
2008-04-04 |
2016-10-05 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ハリコンドリンb類似体
|
EP2415464B1
(en)
|
2009-03-30 |
2017-05-10 |
Eisai R&D Management Co., Ltd. |
Method for producing liposome composition
|
RU2476216C1
(ru)
*
|
2009-03-30 |
2013-02-27 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Липосомальная композиция
|
PE20120923A1
(es)
|
2009-03-30 |
2012-08-27 |
Eisai Randd Man Co Ltd |
Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo
|
WO2010119890A1
(ja)
*
|
2009-04-14 |
2010-10-21 |
日産化学工業株式会社 |
テトラヒドロピラン化合物の製造方法およびその中間体
|
CN102803254B
(zh)
|
2010-01-26 |
2016-09-14 |
卫材R&D管理有限公司 |
用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物
|
EP2686441B1
(en)
|
2011-03-18 |
2019-05-08 |
Eisai R&D Management Co., Ltd. |
Methods and uses for predicting response to eribulin
|
WO2012147900A1
(en)
|
2011-04-28 |
2012-11-01 |
Eisai R&D Management Co., Ltd. |
Microreactor process for halichondrin b analog synthesis
|
ES2705950T3
(es)
|
2011-06-03 |
2019-03-27 |
Eisai R&D Man Co Ltd |
Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
|
WO2013078559A1
(en)
|
2011-11-30 |
2013-06-06 |
Alphora Research Inc. |
Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
|
CN104024237B
(zh)
|
2011-12-16 |
2016-02-24 |
阿方拉研究股份有限公司 |
用于制备3-((2s,5s)-4-亚甲基-5-(3-氧代丙基)四氢呋喃-2-基)丙醇衍生物的方法及其有用的中间体
|
CA2860446C
(en)
*
|
2011-12-29 |
2017-01-10 |
Alphora Research Inc. |
2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
|
EP2831082B1
(en)
*
|
2012-03-30 |
2019-02-20 |
Sandoz AG |
Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
|
AU2013353745A1
(en)
|
2012-12-04 |
2015-06-11 |
Eisai R&D Management Co., Ltd. |
Use of eribulin in the treatment of breast cancer
|
AR096238A1
(es)
|
2013-05-15 |
2015-12-16 |
Alphora Res Inc |
Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo
|
ES2705698T3
(es)
|
2013-06-26 |
2019-03-26 |
Eisai R&D Man Co Ltd |
Terapia de combinación para el tratamiento del cáncer que comprende eribulina y lenvatinib
|
AU2014286880B2
(en)
*
|
2013-07-03 |
2017-12-14 |
Sandoz Ag |
Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing -SO2-(p-TOLYL) groups
|
CN103483352A
(zh)
*
|
2013-10-18 |
2014-01-01 |
李友香 |
抗肿瘤的药用原料药
|
CN114716453A
(zh)
|
2013-11-04 |
2022-07-08 |
卫材R&D管理有限公司 |
软海绵素b的类似物合成中有用的大环化反应和中间体
|
EP3077399B1
(en)
|
2013-12-06 |
2019-02-20 |
Eisai R&D Management Co., Ltd. |
Methods useful in the synthesis of halichondrin b analogs
|
CN104860978A
(zh)
*
|
2014-02-20 |
2015-08-26 |
正大天晴药业集团股份有限公司 |
软海绵素b类似物的合成中间体
|
TW201617326A
(zh)
|
2014-03-06 |
2016-05-16 |
Alphora研發股份有限公司 |
(s)-1-((2r,3r,4s,5s)-5-烯丙-3-甲氧-4-(對甲苯磺醯甲基)四氫呋喃-2-基)-3-氨基丙-2-醇之結晶衍生物
|
KR20170039096A
(ko)
*
|
2014-05-28 |
2017-04-10 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
암의 치료에 있어서 에리불린의 용도
|
EP3160970A4
(en)
|
2014-06-30 |
2017-12-27 |
President and Fellows of Harvard College |
Synthesis of halichondrin analogs and uses thereof
|
JO3783B1
(ar)
|
2014-08-28 |
2021-01-31 |
Eisai R&D Man Co Ltd |
مشتق كوينولين عالي النقاء وطريقة لإنتاجه
|
WO2016038624A1
(en)
|
2014-09-09 |
2016-03-17 |
Cipla Limited |
"process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
|
CN105713031B
(zh)
*
|
2014-12-05 |
2021-05-07 |
正大天晴药业集团股份有限公司 |
一种用于制备艾日布林的中间体及其制备方法
|
DK3263106T3
(da)
|
2015-02-25 |
2024-01-08 |
Eisai R&D Man Co Ltd |
Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
US10945990B2
(en)
|
2015-03-04 |
2021-03-16 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and eribulin for treating cancer
|
WO2016176560A1
(en)
|
2015-04-30 |
2016-11-03 |
President And Fellows Of Harvard College |
Chromium-mediated coupling and application to the synthesis of halichondrins
|
JP6840090B2
(ja)
|
2015-05-07 |
2021-03-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ハリコンドリンマクロライドの合成に有用な大環状化反応および中間体および他のフラグメント
|
US10597401B2
(en)
|
2015-05-08 |
2020-03-24 |
Albany Molecular Research, Inc. |
Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
|
CN107801379B
(zh)
|
2015-06-16 |
2021-05-25 |
卫材R&D管理有限公司 |
抗癌剂
|
US10676481B2
(en)
|
2016-02-12 |
2020-06-09 |
Eisai R&D Management Co., Ltd. |
Intermediates in the synthesis of eribulin and related methods of synthesis
|
WO2017188350A1
(ja)
|
2016-04-28 |
2017-11-02 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍の成長を抑制する方法
|
WO2017203459A1
(en)
|
2016-05-26 |
2017-11-30 |
Dr. Reddy's Laboratories Limited |
Process for preparation of eribulin and intermediates thereof
|
KR102404629B1
(ko)
|
2016-06-30 |
2022-06-02 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
할리콘드린 마크롤리드 및 그의 유사체의 합성에 유용한 프린스 반응 및 중간체
|
US20190263927A1
(en)
|
2016-10-14 |
2019-08-29 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
|
JP6978758B2
(ja)
|
2016-11-11 |
2021-12-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
パラジウム媒介ケトール化
|
BR112019010494A2
(pt)
|
2016-11-23 |
2019-09-17 |
Dr Reddys Laboratories Ltd |
processo para a preparação de eribulina e intermediários do mesmo
|
ES2932832T3
(es)
*
|
2017-01-02 |
2023-01-26 |
Yonsung Fine Chemical Co Ltd |
Intermedio de producción de mesilato de eribulina, y método para producir el mismo
|
KR101991710B1
(ko)
|
2017-12-14 |
2019-06-21 |
연성정밀화학(주) |
에리불린 메실산염의 제조 중간체 및 그의 제조방법
|
KR101880939B1
(ko)
|
2017-01-02 |
2018-08-17 |
연성정밀화학(주) |
에리불린 메실산염의 제조 중간체 및 그의 제조방법
|
CN108341738B
(zh)
*
|
2017-01-24 |
2022-10-21 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的方法及其中间体
|
CN108341828B
(zh)
*
|
2017-01-24 |
2021-04-06 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的方法及其中间体
|
KR102634732B1
(ko)
|
2017-04-05 |
2024-02-13 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
마크로시클릭 화합물 및 그의 용도
|
US9938288B1
(en)
|
2017-04-05 |
2018-04-10 |
President And Fellows Of Harvard College |
Macrocyclic compound and uses thereof
|
BR112020000141A2
(pt)
|
2017-07-06 |
2020-07-14 |
President And Fellows Of Harvard College |
síntese de halicondrinas
|
US11498892B2
(en)
|
2017-07-06 |
2022-11-15 |
President And Fellows Of Harvard College |
Fe/Cu-mediated ketone synthesis
|
US20190046513A1
(en)
|
2017-08-10 |
2019-02-14 |
Huya Bioscience International, Llc |
Combination therapies of hdac inhibitors and tubulin inhibitors
|
CN109694379B
(zh)
*
|
2017-10-24 |
2020-09-11 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的中间体及其制备方法
|
EP3712141B1
(en)
|
2017-11-09 |
2023-07-12 |
Yonsung Fine Chemical Co., Ltd. |
Intermediate for preparing eribulin mesylate and method for preparing same
|
US11407762B2
(en)
|
2017-11-15 |
2022-08-09 |
President And Fellows Of Harvard College |
Macrocyclic compounds and uses thereof
|
WO2019097073A1
(en)
|
2017-11-20 |
2019-05-23 |
Basilea Pharmaceutica International AG |
Pharmaceutical combinations for use in the treatment of neoplastic diseases
|
US11008296B2
(en)
|
2017-11-21 |
2021-05-18 |
Natco Pharma Limited |
Intermediates for the preparation of eribulin thereof
|
MX2020006945A
(es)
|
2018-01-03 |
2020-11-09 |
Eisai R&D Man Co Ltd |
Reaccion de prins y compuestos utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.
|
WO2019211877A1
(en)
|
2018-05-03 |
2019-11-07 |
Cipla Limited |
Process for the preparation of macrocyclic ketone analogs of halichondrin b
|
WO2020008382A1
(en)
*
|
2018-07-04 |
2020-01-09 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of eribulin and intermediates thereof
|
WO2020016847A2
(en)
*
|
2018-07-20 |
2020-01-23 |
Dr. Reddy’S Laboratories Limited |
Purification process for preparation of eribulin and intermediates thereof
|
US20210340156A1
(en)
*
|
2018-10-09 |
2021-11-04 |
Dr. Reddy's Laboratories Limited |
Process for preparation of eribulin and intermediates thereof
|
US11447499B2
(en)
|
2019-06-14 |
2022-09-20 |
Rk Pharma Inc. |
Process for the preparation of eribulin mesylate intermediate
|
US20220333139A1
(en)
|
2019-06-21 |
2022-10-20 |
Council Of Scientific And Industrial Research |
A Chemo-Enzymatic Process for the Preparation of Homopropargylic Alcohol
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
US11572414B2
(en)
|
2019-11-07 |
2023-02-07 |
Eisai R&D Management Co., Ltd. |
Eribulin antibody-drug conjugates and methods of use
|
CN113135876A
(zh)
*
|
2020-01-16 |
2021-07-20 |
南通诺泰生物医药技术有限公司 |
艾日布林及其中间体的制备方法
|
JP2023511163A
(ja)
*
|
2020-01-22 |
2023-03-16 |
上海森輝医薬有限公司 |
エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
|
KR102377262B1
(ko)
|
2020-05-11 |
2022-03-22 |
연성정밀화학(주) |
결정성 에리불린 염
|
IL279168B
(en)
*
|
2020-12-02 |
2022-04-01 |
Finetech Pharmaceutical Ltd |
A process for the preparation of eribulin
|
CN113354659B
(zh)
|
2021-06-08 |
2022-04-08 |
江苏慧聚药业股份有限公司 |
甲磺酸艾日布林的合成
|
TW202310878A
(zh)
*
|
2021-07-22 |
2023-03-16 |
大陸商上海森輝醫藥有限公司 |
艾日布林衍生物的藥物偶聯物
|
WO2023212746A2
(en)
*
|
2022-04-30 |
2023-11-02 |
William Marsh Rice University |
A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
|